No benefit of vorapaxar on walking performance in patients with intermittent claudication

1. Hamburg, NM, Creager, MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circulation 2017; 81: 281–289.
Google Scholar | Crossref2. Narula, N, Dannenberg, AJ, Olin, JW, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol 2018; 72: 2152–2163.
Google Scholar | Crossref | Medline3. Gerhard-Herman, MD, Gornik, HL, Barrett, C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135: e726–e779.
Google Scholar | Crossref | Medline | ISI4. Berger, JS, Hiatt, WR. Medical therapy in peripheral artery disease. Circulation 2012; 126: 491–500.
Google Scholar | Crossref | Medline | ISI5. Singer, E, Imfeld, S, Staub, D, et al. Effect of aspirin versus clopidogrel on walking exercise performance in intermittent claudication—A double-blind randomized multicenter trial. J Am Heart Assoc 2012; 1: 51–56.
Google Scholar | Crossref | Medline6. Leger, AJ, Covic, L, Kuliopulos, A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070–1077.
Google Scholar | Crossref | Medline | ISI7. McDermott, MM . Lower extremity manifestations of peripheral artery disease: The pathophysiologic and functional implications of leg ischemia. Circ Res 2015; 116: 1540–1550.
Google Scholar | Crossref | Medline | ISI8. Wang, A . Review of vorapaxar for the prevention of atherothrombotic events. Expert Opin Pharmacother 2015; 16: 2509–2522.
Google Scholar | Crossref | Medline9. Bonaca, MP, Gutierrez, JA, Creager, MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: Results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133: 997–1005.
Google Scholar | Crossref | Medline | ISI10. Bonaca, MP, Scirica, BM, Creager, MA, et al. Vorapaxar in patients with peripheral artery disease: Results from TRA2°P-TIMI 50. Circulation 2013; 127: 1522–1529.
Google Scholar | Crossref | Medline | ISI11. Gardner, AW, Parker, DE, Montgomery, PS, et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: A randomized controlled trial. Circulation 2011; 123: 491–498.
Google Scholar | Crossref | Medline | ISI12. Murphy, TP, Cutlip, DE, Regensteiner, JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: Six-month outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) study. Circulation 2012; 125: 130–139.
Google Scholar | Crossref | Medline | ISI13. Morrow, DA, Braunwald, E, Bonaca, MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404–1413.
Google Scholar | Crossref | Medline | ISI14. Tricoci, P, Huang, Z, Held, C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20–33.
Google Scholar | Crossref | Medline | ISI15. Hess, CN, Hiatt, WR. Antithrombotic therapy for peripheral artery disease in 2018. JAMA 2018; 319: 2329–2330.
Google Scholar | Crossref | Medline16. Anand, SS, Bosch, J, Eikelboom, JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219–229.
Google Scholar | Crossref | Medline17. Norgren, L, Hiatt, WR, Dormandy, JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45(Suppl S): S5–67.
Google Scholar | Crossref | Medline | ISI18. Beebe, HG, Dawson, DL, Cutler, BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041–2050.
Google Scholar | Crossref | Medline19. Dawson, DL, Cutler, BS, Meissner, MH, Strandness, DE Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678–686.
Google Scholar | Crossref | Medline | ISI20. Dawson, DL, Cutler, BS, Hiatt, WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523–530.
Google Scholar | Crossref | Medline | ISI21. Shahin, Y, Cockcroft, JR, Chetter, IC. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br J Surg 2013; 100: 1154–1163.
Google Scholar | Crossref | Medline | ISI22. Abbott, JD . Lessons learned from recent randomized clinical trials for intermittent claudication. Circ Cardiovasc Interv 2012; 5: 139–141.
Google Scholar | Crossref | Medline23. Gerhard-Herman, MD, Gornik, HL, Barrett, C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2017; 135: e686–e725.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif